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Question
Are there missed opportunities for measles-mumps-rubella (MMR) vaccination at pretravel consultations
for US pediatric international travelers?
Findings
In this cross-sectional study of 14 602 pediatric travelers, 91.7% of infants, 59.6% of preschool-aged
travelers, and 3.2% of school-aged travelers were eligible for MMR vaccination; however, 44.1% of MMR
vaccination–eligible infants, 56.5% of MMR vaccination–eligible preschool-aged travelers, and 88.5% of
MMR vaccination–eligible school-aged travelers were not vaccinated at the consultation. Clinician
decision and guardian refusal were the most common reasons for nonvaccination.
Meaning
The findings suggest that opportunities exist for clinicians to provide pretravel MMR vaccination to US
pediatric travelers and that additional education of clinicians and guardians may be needed.

Abstract
Importance
The US population is experiencing a resurgence of measles, with more than 1000 cases during the first 6
months of 2019. Imported measles cases among returning international travelers are the source of most US
measles outbreaks, and these importations can be reduced with pretravel measles-mumps-rubella (MMR)
vaccination of pediatric travelers. Although it is estimated that children account for less than 10% of US
international travelers, pediatric travelers account for 47% of all known measles importations.
Objective
To examine clinical practice regarding MMR vaccination of pediatric international travelers and to identify
reasons for nonvaccination of pediatric travelers identified as MMR eligible.
Design, Setting, and Participants
This cross-sectional study of pediatric travelers (ages ≥6 months and <18 years) attending pretravel
consultation at 29 sites associated with Global TravEpiNet (GTEN), a Centers for Disease Control and
Prevention–supported consortium of clinical sites that provide pretravel consultations, was performed from
January 1, 2009, through December 31, 2018.
Main Outcomes and Measures
Measles-mumps-rubella vaccination among MMR vaccination–eligible pediatric travelers.
Results
Of 14 602 pretravel consultations for pediatric international travelers, 2864 travelers (19.6%; 1475 [51.5%]
males; 1389 [48.5%] females) were eligible to receive pretravel MMR vaccination at the time of the
consultation: 365 of 398 infants aged 6 to 12 months (91.7%), 2161 of 3623 preschool-aged travelers aged
1 to 6 years (59.6%), and 338 of 10 581 school-aged travelers aged 6 to 18 years (3.2%). Of 2864 total
MMR vaccination–eligible travelers, 1182 (41.3%) received the MMR vaccine and 1682 (58.7%) did not.
The MMR vaccination–eligible travelers who did not receive vaccine included 161 of 365 infants (44.1%),
1222 of 2161 preschool-aged travelers (56.5%), and 299 of 338 school-aged travelers (88.5%). We
observed a diversity of clinical practice at different GTEN sites. In multivariable analysis, MMR
vaccination–eligible pediatric travelers were less likely to be vaccinated at the pretravel consultation if
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable
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they were school-aged (model 1: odds ratio [OR], 0.32 [95% CI, 0.24-0.42; P < .001]; model 2: OR, 0.26
[95% CI, 0.14-0.47; P < .001]) or evaluated at specific GTEN sites (South: OR, 0.06 [95% CI, 0.01-0.52;
P < .001]; West: OR, 0.10 [95% CI, 0.02-0.47; P < .001]). The most common reasons for nonvaccination
were clinician decision not to administer MMR vaccine (621 of 1682 travelers [36.9%]) and guardian
refusal (612 [36.4%]).
Conclusions and Relevance
Although most infant and preschool-aged travelers evaluated at GTEN sites were eligible for pretravel
MMR vaccination, only 41.3% were vaccinated during pretravel consultation, mostly because of clinician
decision or guardian refusal. Strategies may be needed to improve MMR vaccination among pediatric
travelers and to reduce measles importations and outbreaks in the United States.

Introduction
The United States has had a resurgence of measles. More than 1000 cases were reported from 28 states
within the first 6 months of 2019, which is the greatest number of cases in the United States since 2000.1
Measles is a viral illness associated with fever, cough, coryza, and conjunctivitis followed by rash that can
result in hospitalization, severe neurologic disease, and death.2,3 A safe and effective measles-mumpsrubella (MMR) vaccine is included in the routine childhood vaccination schedule in the United States,4,5,6
and widespread vaccine coverage has ensured maintenance of measles elimination (ie, lack of sustained
measles transmissions for >12 months) in the United States since 2000.7 Although MMR vaccination rates
are stable at the national level,8 refused or delayed MMR vaccination among healthy children has
increased, and communities with large numbers of incompletely vaccinated children are highly susceptible
to outbreaks.9 This major public health concern jeopardizes the elimination of measles in the United
States.1,10
Since elimination in 2000, measles outbreaks in the United States have been associated with international
importation, and more than half of all measles importations occur among US residents who are infected
during international travel.11,12 However, the risk of measles exposure during international travel is often
underrecognized by clinicians and travelers. At pretravel consultations in the Global TravEpiNet (GTEN)
Consortium from 2009 through 2014, clinicians identified 16% of US adult international travelers born
after 1956 as eligible for pretravel MMR vaccination before travel, yet only 47% of these individuals were
vaccinated.13
Pediatric travelers are a particularly important group for pretravel MMR vaccination. Although pediatric
travelers comprise less than 10% of US international travelers annually,14 they accounted for 47% of
measles importations among returning US travelers from 2001 through 2016.11,12 The Advisory
Committee on Immunization Practices (ACIP) recommends that US children without other evidence of
immunity receive 2 lifetime MMR doses as part of routine vaccination; the first dose is given between 12
and 15 months of age and a second dose between 4 and 6 years of age (Table 1).6 Since 1989, ACIP has
recommended a specific schedule of MMR vaccination among pediatric international travelers.15,16
Infants (aged 6 to <12 months) should receive 1 MMR vaccine dose before international travel that does
not count toward the 2 lifetime doses. Preschool-aged travelers (aged 1 to <6 years) should receive both
lifetime MMR doses before departure, at least 28 days apart. The ACIP recommendations for international
travelers do not differ from the routine immunization schedule for school-aged children and adolescents
(aged 6 to <18 years), who should have already received 2 MMR doses during routine care.15
The objective of this multisite observational study was to characterize clinical practice regarding MMR
vaccination of pediatric travelers seen for pretravel consultation. We characterized how frequently
clinicians identified pediatric travelers eligible for MMR vaccination. We then examined whether MMR
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable
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vaccination was administered during the pretravel consultation and reasons for nonvaccination.

Methods
Study Setting
This cross-sectional study used data from the Global TravEpiNet (GTEN), a consortium of US clinical
sites, supported by the Centers for Disease Control and Prevention, where clinicians evaluate travelers in
anticipation of upcoming travel; data have been prospectively collected since 2009 regarding clinical
practice patterns.17 Twenty-nine sites contributed data to this analysis from 4 US census regions: Northeast
(9 sites), Midwest (2 sites), West (8 sites), and South (10 sites).18 Nineteen sites were academic centers,
and 10 were other types of health facilities, including primary care practices, pharmacies, and public health
clinics. Institutional review board approval was obtained at all participating GTEN sites (eTable 1 in the
Supplement). The institutional review boards that reviewed the study at participating clinical sites waived
the need for written or oral informed consent because the study collected only deidentified data that are
routinely collected during a standard clinical encounter.
Study Population and Eligibility Criteria
Travelers were eligible for inclusion if they were younger than 18 years when they attended a GTEN site
from January 1, 2009, through December 31, 2018. We excluded data on pediatric travelers whose
itineraries were restricted to the United States or who were younger than 6 months at the pretravel
consultation because they would not be eligible for ACIP-recommended pretravel MMR vaccination.15,16
We characterized pediatric travelers into 3 age groups given age-stratified ACIP guidelines for MMR
vaccination (Table 1): infants (aged 6 to <12 months), preschool-aged children (aged 1 to <6 years), and
school-aged children and adolescents (aged 6 to <18 years).
Data Collection
Clinicians used a structured, online questionnaire during pretravel consultations to confirm details entered
by the traveler or guardian regarding demographics, medical conditions, and travel itinerary (eg, region,
purpose, and duration of travel).17 Clinicians entered data about immunization history based on traveler or
guardian report or written documentation, as well as health advice provided, vaccines administered, and
medications prescribed. Incomplete answers were not allowed.
Assessment of MMR Vaccination Eligibility
We reviewed the data that clinicians entered in the GTEN structured questionnaire to classify travelers as
eligible for MMR vaccination according to our age-stratified study definition: infants (aged 6 to <12
months), if clinicians noted no previous MMR vaccination and no alternative evidence of immunity; or
children older than 1 year (ie, preschool-aged and school-aged travelers), if clinicians did not elicit a
history of 2 MMR vaccine doses or other evidence of immunity.15,16 We considered pediatric travelers to
be ineligible for MMR vaccination if they had evidence of preexisting measles immunity, had
contraindications to MMR vaccination (ie, immunosuppression), or had received a dose of MMR vaccine
less than 28 days before the pretravel consultation.
Clinical Management
Clinicians assessed travelers’ past MMR vaccination status and administered MMR vaccine doses
according to their clinical practice. When clinicians identified travelers as eligible for MMR vaccination,
the structured questionnaire prompted clinicians to consider MMR vaccination and to select 1 reason for
nonvaccination from a list of possibilities available for any travel-related vaccination: not indicated for this
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable
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patient or itinerary, insufficient time before departure, guardian refusal, or referral to another clinician for
vaccination.13 If clinicians failed to identify travelers who were eligible for MMR vaccination, the
structured questionnaire did not prompt clinicians to provide a reason for nonvaccination.
Reasons for nonvaccination were grouped into 3 categories: clinician decision, guardian refusal, or referral
to another clinician. Because MMR vaccination is indicated for all MMR vaccination–eligible
international travelers regardless of itinerary and at any time before departure, we categorized encounters
as clinician decision if the clinician (1) failed to identify an MMR vaccination–eligible traveler (ie, traveler
met the study definition of MMR vaccination eligibility, but the clinician misclassified as ineligible) or (2)
selected the answers, “not indicated for this traveler or itinerary” or “insufficient time before departure.”
Before 2012, guardian refusal of MMR vaccination was recorded without a more specific reason.
Beginning in 2012, clinicians recorded 1 of 3 reasons for guardian refusal: (1) lack of concern about
illness, (2) concerns about vaccine safety, or (3) concerns about cost. Clinicians could also note that the
MMR vaccine was not available at the pretravel consultation.
Statistical Analyses
Destinations were grouped into 6 geographic regions as defined by the World Health Organization.19 The
most common purposes of pediatric travel were (1) leisure, (2) visiting friends and relatives, or (3)
nonmedical service work or education. We defined travelers as visiting friends and relatives if they
reported traveling to a region of origin of self or family to visit friends or relatives or residing with
relatives in a low- or middle-income country.17,20 We grouped additional reasons for travel (eg, business)
as other because they were infrequent. We calculated the time between pretravel consultation and
departure.
We obtained distributions of traveler and site characteristics among all pediatric travelers and MMR
vaccination–eligible travelers, stratified by age group. We examined whether the distribution of
characteristics varied by whether the vaccine was administered to MMR vaccination–eligible travelers or
by reasons for nonvaccination among the MMR vaccination–eligible travelers who were not vaccinated.
Odds ratios (ORs) with 95% CIs were obtained from 2 separate multivariable logistic regressions to assess
the association of vaccination of MMR vaccination–eligible pediatric travelers with traveler sex, age
group, region, purpose and duration of travel, and time to departure. Model 1 also included type of site,
whereas model 2 included US census region. Although vaccination rates varied by the type of site and
census region, we were unable to include both variables in a single model or study the interaction of these
2 variables because of the unequal distribution of academic and nonacademic sites across the US census
regions and insufficient sample sizes. The multivariable models used Taylor linearization methods to
adjust for the clustering of patients within sites. Analyses were conducted using SAS, version 9.2 (SAS
Institute Inc) and SUDAAN, version 11.0.3 (RTI International). We considered a 2-sided P < .05 to be
statistically significant.

Results
Of the 121 295 pretravel consultations at 29 GTEN sites from January 1, 2009, through December 31,
2018, pediatric travelers comprised 14 802 (12.2%) consultations (eFigure in the Supplement). We
excluded 12 pediatric travelers reporting destinations only within the United States or associated territories
and 188 travelers younger than 6 months. Demographics from these 14 602 pediatric travel consultations
are presented in Table 2 and are stratified by age group in eTable 2 in the Supplement.
MMR Vaccination–Eligible Pediatric Travelers

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable
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Among 14 602 pretravel consultations for pediatric travelers, we identified 11 708 pediatric travelers
(80.2%) who were not eligible for MMR vaccination and 2864 (19.6%; 1475 [51.5%] males; 1389 [48.5%]
females) who were eligible. Of all travelers, 0.3% had medical contraindications or received the first dose
of MMR vaccine within the previous 28 days (eFigure in the Supplement).
Eligibility for MMR vaccination varied substantially by age group (eFigure in the Supplement). Infants
were most frequently eligible for MMR vaccination (365 of 398 travelers [91.7%]), whereas 2161 of 3623
preschool-aged travelers (59.6%) were eligible. School-aged travelers were rarely eligible (338 of 10 581
travelers [3.2%]).
Nonvaccination of MMR Vaccination–Eligible Pediatric Travelers
Pediatric travelers who were eligible for MMR vaccination were not vaccinated at 1682 of 2864 GTEN
pretravel consultations (58.7%) (Figure 1). Among these MMR vaccination–eligible individuals, 161 of
365 infants (44.1%), 1222 of 2161 preschoolers (56.5%), and 299 of 338 school-aged travelers (88.5%)
were not vaccinated.
Reasons for nonvaccination of 1682 MMR vaccination–eligible travelers included clinician decision (621
travelers [36.9%]), guardian refusal (612 [36.4%]), referral to another clinician (433 [25.7%]), and vaccine
unavailable (16 [1.0%]) (Figure 1). Among the 621 consultations in which clinicians decided not to
vaccinate MMR vaccination–eligible travelers, clinicians failed to identify MMR vaccination eligibility in
475 consultations (76.5%), incorrectly endorsed that MMR vaccination was not indicated in 104
consultations (16.7%), and incorrectly cited insufficient time for vaccination in 42 consultations (6.8%).
Most guardians (75% for infants, 88% for preschool-aged, and 89% for school-aged) who refused MMR
vaccination cited a lack of concern about measles illness and rarely expressed concerns about MMR
vaccination safety or cost (Figure 1). Clinician decision occurred most often among infants (70 of 161
[43.5%]) and preschool-aged travelers (497 of 1222 [40.7%]), whereas guardians refused most frequently
for school-aged travelers (187 of 299 [62.5%]). Referral to another clinician occurred for 63 of 161 infants
(39.1%), 314 of 1222 preschoolers (25.7%), and 56 of 299 school-aged travelers (18.7%) who were
eligible for MMR vaccination but were not vaccinated.
Characteristics of MMR Vaccination–Eligible Travelers
We examined the traveler and site characteristics of all pretravel consultations at which MMR vaccination–
eligible pediatric travelers were vaccinated compared with consultations at which these individuals were
not vaccinated (Table 2 and eTable 3 in the Supplement). Of 2864 total MMR vaccination–eligible
travelers, 1182 (41.3%) were vaccinated and 1682 (58.7%) were not vaccinated. The MMR vaccination–
eligible travelers were less likely to be vaccinated if they were school-aged, were traveling within North
and South America, were traveling fewer than 14 days, or were evaluated at a nonacademic center or in the
South or West region of the United States. The MMR vaccination–eligible travelers were more likely to be
vaccinated if they were visiting friends or relatives or if they were traveling to Africa.
In both multivariable models (Table 3), MMR vaccination–eligible travelers were more likely to be
vaccinated if they were traveling to Africa (model 1: OR, 1.86 [95% CI, 1.15-3.01], P = .008; model 2:
OR, 1.74 [95% CI, 1.17-2.58], P = .004) and were less likely to be vaccinated if they were school-aged
(model 1: OR, 0.32 [95% CI, 0.24-0.42], P < .001; model 2: OR, 0.26 [95% CI, 0.14-0.47], P < .001). They
were also less likely to be vaccinated if they were traveling for leisure (Model 1: OR, 0.49; 95% CI, 0.260.94; model 2: OR, 0.64 [95% CI, 0.38-1.08]), service or education (model 1: OR, 0.18 [95% CI, 0.070.48]; model 2: OR, 0.47 [95% CI, 0.16-1.34]), or other purposes (model 1: OR, 0.60 [95% CI, 0.36-1.00];
model 2: OR, 0.77 [95% CI, 0.49-1.19]) compared with visiting friends and relative (P = .002). They were
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less likely to be vaccinated if they were evaluated at nonacademic centers in model 1 (OR, 0.04; 95% CI,
0.01-0.20; P < .001) or at GTEN sites in the South (OR, 0.06; 95% CI, 0.01-0.52; P < .001) or West (OR,
0.10; 95% CI, 0.02-0.47; P < .001) in model 2.
Specific reasons for nonvaccination among MMR vaccination–eligible travelers were also associated with
traveler and site characteristics (Table 2 and eTable 3 in the Supplement). Clinician decision to not
vaccinate was more common in evaluation of travelers with 1 previous MMR vaccination or at academic
centers or in the Northeast. Guardians were more likely to refuse MMR vaccination for school-aged
travelers, travel to Africa, itineraries of at least 14 days, or at nonacademic centers or sites in the South.
Guardians of preschool-aged and school-aged travelers with no previous MMR vaccinations were also
more likely to refuse MMR vaccination. Referral to another clinician occurred more frequently when
departure was at least 14 days after pretravel consultation among infants or preschool-aged travelers or at
sites in the West.
A wide range of clinical practice was evident among the GTEN sites (Figure 2 and eTable 4 in the
Supplement). Travelers eligible for MMR vaccination were more frequently not vaccinated at
nonacademic centers in the Northeast (100%), nonacademic centers in the South (97.1%), and academic
centers in the West (94.8%) compared with 36.0% to 59.1% at other sites. The most common reasons for
nonvaccination varied by site: clinician decision (nonacademic centers in the Northeast and Midwest),
guardian refusal (nonacademic centers in the South), and referral to another clinician (academic centers in
the West).

Discussion
These data from the largest US consortium of clinicians offering pretravel consultations showed that
19.6% of pediatric international travelers were eligible for pretravel MMR vaccination, yet 58.7% were not
vaccinated during the consultation despite evaluation by clinicians experienced in pretravel consultations.
These missed opportunities were attributable in similar proportions to clinician decision not to vaccinate
and guardian refusal. A better understanding of the benefits of MMR vaccination and the risks of measles
illness is essential among clinicians and guardians to improve measles immunity among pediatric
international travelers before travel and potentially reduce measles importations to the United States.
In more than 40% (43.5% of infant travelers; 40.7% of preschool-aged travelers) of pretravel consultations
with MMR vaccination–eligible infant and preschool-aged travelers who were not vaccinated, clinicians
had not recommended MMR vaccination, which underscores major knowledge gaps even among this
group of clinicians with expertise in travel medicine and vaccinations. Infants and preschool-aged travelers
are at high risk for serious disease with measles infection and are unlikely to have had appropriate previous
MMR vaccinations.2,3 Although MMR vaccination is safe for children aged 6 to 12 months, it is not
routinely recommended because of the low likelihood of measles exposure in the United States. There is
also lower effectiveness when given to children younger than 12 months (ie, 85% instead of 93% with 1
dose) because of potential interference by maternal antibodies and immaturity of the immune
system.15,21,22 However, infants at high risk for measles exposure, such as international travelers, should
be offered early MMR vaccination followed by the standard 2 MMR vaccinations after 12 months of
age.15,16 An investigation of reasons why clinicians did not identify MMR vaccination–eligible travelers
or did not administer MMR vaccination is needed to educate clinicians and to improve implementation of
ACIP recommendations for MMR vaccination of pediatric travelers.
Only 3% of school-aged travelers were eligible for MMR vaccination in this study, reflecting the overall
high uptake of routine vaccines in the United States.23,24 However, those identified as eligible for MMR
vaccination were usually not vaccinated at the pretravel consultation because of guardian refusal. Vaccinehesitant guardians are commonly noted to minimize concerns about vaccine-preventable disease,25,26
which is notable because the study period included major measles outbreaks with robust media
2 28 29
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27,28,29

coverage.
Clinicians should preemptively discuss beliefs regarding the risks of becoming infected
with measles and the realities of clinical illness with measles. School-aged travelers should already have
received 2 MMR vaccinations routinely; however, 11.5% (39 of 338) MMR vaccination–eligible schoolaged travelers in this study were successfully vaccinated at the pretravel consultation. Clinicians are
trusted sources of information about vaccinations and should take advantage of every opportunity to
address vaccine effectiveness, even in the context of previous vaccine refusal.
Referral to another clinician for MMR vaccination was common among pediatric travelers of all age
groups in our study, particularly when there were 14 days or more between the pretravel consultation and
departure. Previous GTEN analyses have shown that routine vaccinations are less likely to be administered
at pretravel consultations than travel-related vaccinations,30 which may reflect clinicians’ concerns that
routine vaccinations can prompt higher out-of-pocket costs for the traveler and family or might not be
recorded in the travelers’ permanent medical record if given at pretravel consultations. However, missed
opportunities for MMR vaccination remain likely because families may not pursue another health care
appointment before travel.
These data from GTEN sites likely underestimated the percentage of MMR vaccination–eligible pediatric
travelers. Clinicians followed their typical clinical practice and were not required to accept only written
documentation of previous MMR vaccinations or other evidence for immunity. If strict ACIP criteria had
been required, an even greater proportion of pediatric travelers may have been considered to be eligible for
MMR vaccination. In addition, primary care practices may be less likely to consider and recommend
pretravel MMR vaccination for eligible pediatric travelers, in contrast to GTEN clinicians who are travel
medicine specialists. This is of particular concern for travelers to Europe, who are rarely referred for
pretravel consultation (ie, only 3% of the pediatric travelers evaluated at GTEN sites had itineraries
restricted to Europe). Measles remains widespread in Europe, and travelers returning from Europe
accounted for 30% of imported measles cases to the United States from 2001 through 2016.12,31 Ensuring
measles immunity among international travelers is essential and can only be improved if primary care
pediatricians also discuss pretravel MMR vaccination recommendations with pediatric travelers and their
guardians at routine visits.

Limitations
These data are from a large, prospective, multisite study, but our analysis has limitations. Although the
observed patterns of reported vaccination were consistent with US coverage levels, our estimates of MMR
vaccination eligibility may be underestimates or overestimates because we did not have access to written
documentation of previous immunizations.8,23,24 Health-seeking behavior may be more likely among
travelers and families who pursue pretravel consultation; such travelers may be more likely to be up to date
on routine vaccines and to follow recommendations about additional vaccinations. An even greater
proportion of US travelers might lack measles immunity or refuse vaccination if recommended. These
GTEN data showed diverse clinical practices at different types of sites in different regions of the United
States that may not be representative of any specific region; the uneven distribution of the types of sites
across the US census regions and relatively small sample sizes precluded accounting for both variables
simultaneously in the multivariable models. Our data were not representative of travelers to international
settings who did not attend specialized pretravel consultation.

Conclusions
We observed extensive missed opportunities for MMR vaccination among eligible pediatric travelers.
Clinicians often did not administer pretravel MMR vaccination, even for vulnerable infants and preschoolaged travelers, and guardians did not recognize measles as a serious illness. Strategies may be needed to
improve clinician and guardian knowledge of measles as a serious travel-related illness and the benefits of
MMR vaccination, particularly in the setting of ongoing US measles outbreaks.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable

9/20

5/18/2021

Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers

Notes

Supplement.

eTable 1. IRB Approvals for Participating Global TravEpiNet sites.
eTable 2. Baseline Demographics of All Eligible Pediatric Travelers and MMR-eligible Pediatric
Travelers Attending GTEN Sites From 2009 Through 2018.
eTable 3. Baseline Demographics of MMR-eligible Travelers Attending GTEN Sites From 2009
Through 2018, Stratified by Age Group.
eTable 4. MMR-eligibility, Vaccination, and Reasons for Nonvaccination Among Pediatric
Travelers at Academic Sites and Nonacademic Sites, Stratified by Region of GTEN Site.
eFigure. Assessment of MMR Eligibility Among Pediatric Travelers at Pretravel Consultations at
GTEN Sites From 2009 Through 2018.

References
1. Centers for Disease Control and Prevention. Measles (rubeola): measles cases and outbreaks: measles
cases in 2019. https://www-cdc-gov.medproxy.hofstra.edu/measles/cases-outbreaks.html. Published June
20, 2019. Accessed September 12, 2019.
2. Wendorf KA, Winter K, Zipprich J, et al. . Subacute sclerosing panencephalitis: the devastating measles
complication that might be more common than previously estimated. Clin Infect Dis. 2017;65(2):-.
doi:10.1093/cid/cix302 [PubMed: 28387784] [CrossRef: 10.1093/cid/cix302]
3. Moss WJ, Griffin DE. Measles. Lancet. 2012;379(9811):153-164. doi:10.1016/S0140-6736(10)62352-5
[PubMed: 21855993] [CrossRef: 10.1016/S0140-6736(10)62352-5]
4. Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT. Adverse events
following measles, mumps, and rubella vaccine in adults reported to the Vaccine Adverse Event Reporting
System (VAERS), 2003–2013. Clin Infect Dis. 2015;60(10):e58-e65. doi:10.1093/cid/civ061
[PMCID: PMC4447805] [PubMed: 25637587] [CrossRef: 10.1093/cid/civ061]
5. Jain A, Marshall J, Buikema A, Bancroft T, Kelly JP, Newschaffer CJ. Autism occurrence by MMR
vaccine status among US children with older siblings with and without autism. JAMA. 2015;313(15):15341540. doi:10.1001/jama.2015.3077 [PubMed: 25898051] [CrossRef: 10.1001/jama.2015.3077]
6. Centers for Disease Control and Prevention. Immunization schedules: child and adolescent
immunization schedule. https://www-cdc-gov.medproxy.hofstra.edu/vaccines/schedules/hcp/imz/childadolescent.html. Published February 5, 2019. Accessed September 12, 2019.
7. Papania MJ, Wallace GS, Rota PA, et al. . Elimination of endemic measles, rubella, and congenital
rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr. 2014;168(2):148-155.
doi:10.1001/jamapediatrics.2013.4342 [PubMed: 24311021] [CrossRef:
10.1001/jamapediatrics.2013.4342]
8. Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination coverage among children aged
19–35 months—United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(40):1123-1128.
doi:10.15585/mmwr.mm6740a4 [PMCID: PMC6181261] [PubMed: 30307907] [CrossRef:
10.15585/mmwr.mm6740a4]

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable

10/20

5/18/2021

Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers

9. Olive JK, Hotez PJ, Damania A, Nolan MS. The state of the antivaccine movement in the United States:
a focused examination of nonmedical exemptions in states and counties. PLoS Med. 2018;15(6):e1002578.
doi:10.1371/journal.pmed.1002578 [PMCID: PMC5997312] [PubMed: 29894470] [CrossRef:
10.1371/journal.pmed.1002578]
10. Majumder MS, Cohn EL, Mekaru SR, Huston JE, Brownstein JS. Substandard vaccination compliance
and the 2015 measles outbreak. JAMA Pediatr. 2015;169(5):494-495.
doi:10.1001/jamapediatrics.2015.0384 [PMCID: PMC4476536] [PubMed: 25774618] [CrossRef:
10.1001/jamapediatrics.2015.0384]
11. Fiebelkorn AP, Redd SB, Gastañaduy PA, et al. . A comparison of postelimination measles
epidemiology in the United States, 2009-2014 versus 2001-2008. J Pediatric Infect Dis Soc. 2017;6(1):4048. doi:10.1093/jpids/piv080 [PMCID: PMC4905815] [PubMed: 26666559] [CrossRef:
10.1093/jpids/piv080]
12. Lee AD, Clemmons NS, Patel M, Gastañaduy PA. International importations of measles virus into the
United States during the postelimination era, 2001–2016. J Infect Dis. 2019; 219(10):1616-1623.
doi:10.1093/infdis/jiy701 [PMCID: PMC6474820] [PubMed: 30535027] [CrossRef:
10.1093/infdis/jiy701]
13. Hyle EP, Rao SR, Jentes ES, et al. . Missed opportunities for measles, mumps, rubella vaccination
among departing US adult travelers receiving pretravel health consultations. Ann Intern Med.
2017;167(2):77-84. doi:10.7326/M16-2249 [PMCID: PMC5513758] [PubMed: 28505632] [CrossRef:
10.7326/M16-2249]
14. National Travel & Tourism Office. 2017 Profile of US resident travelers visiting overseas destinations
(outbound). 2017. https://travel-tradegov.medproxy.hofstra.edu/outreachpages/outbound.general_information.outbound_overview.asp. Accessed
November 1, 2019.
15. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS; Centers for Disease Control and Prevention .
Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary
recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.
2013;62(RR-04):1-34. [PubMed: 23760231]
16. Centers for Disease Control (CDC) Measles prevention. MMWR Suppl. 1989;38(9):1-18. [PubMed:
2513473]
17. LaRocque RC, Rao SR, Lee J, et al. ; Global TravEpiNet Consortium . Global TravEpiNet: a national
consortium of clinics providing care to international travelers—analysis of demographic characteristics,
travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect
Dis. 2012;54(4):455-462. doi:10.1093/cid/cir839 [PubMed: 22144534] [CrossRef: 10.1093/cid/cir839]
18. US Census Bureau. Census regions and divisions of the United States. https://www2-censusgov.medproxy.hofstra.edu/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf. Accessed September 12,
2019.
19. World Health Organization. WHO regional offices. https://www-whoint.medproxy.hofstra.edu/about/regions/en/. Accessed September 12, 2019.
20. Centers for Disease Control and Prevention CDC Yellow Book 2018: Health Information for
International Travel. New York, NY: Oxford University Press; 2017.
21. Gastañaduy PA, Goodson JL. Measles (rubeola) In: CDC Yellow Book 2018: Health Information for
International Travel. New York, NY: Oxford University Press; 2017.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable

11/20

5/18/2021

Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers

22. Woo EJ, Winiecki SK, Arya D, Beeler J. Adverse events after MMR or MMRV vaccine in infants
under nine months old. Pediatr Infect Dis J. 2016;35(8):e253-e257. doi:10.1097/INF.0000000000001201
[PubMed: 27167117] [CrossRef: 10.1097/INF.0000000000001201]
23. Mellerson JL, Maxwell CB, Knighton CL, Kriss JL, Seither R, Black CL. Vaccination coverage for
selected vaccines and exemption rates among children in kindergarten—United States, 2017-18 school
year. MMWR Morb Mortal Wkly Rep. 2018;67(40):1115-1122. doi:10.15585/mmwr.mm6740a3
[PMCID: PMC6181259] [PubMed: 30307904] [CrossRef: 10.15585/mmwr.mm6740a3]
24. Walker TY, Elam-Evans LD, Yankey D, et al. . National, regional, state, and selected local area
vaccination coverage among adolescents aged 13–17 years—United States, 2017. MMWR Morb Mortal
Wkly Rep. 2018;67(33):909-917. doi:10.15585/mmwr.mm6733a1 [PMCID: PMC6107323] [PubMed:
30138305] [CrossRef: 10.15585/mmwr.mm6733a1]
25. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: causes, consequences, and a call to
action. Am J Prev Med. 2015;49(6)(suppl 4):S391-S398. doi:10.1016/j.amepre.2015.06.009 [PubMed:
26337116] [CrossRef: 10.1016/j.amepre.2015.06.009]
26. Blaisdell LL, Gutheil C, Hootsmans NA, Han PK. Unknown risks: parental hesitation about
vaccination. Med Decis Making. 2016;36(4):479-489. doi:10.1177/0272989X15607855 [PubMed:
26506958] [CrossRef: 10.1177/0272989X15607855]
27. Gastañaduy PA, Budd J, Fisher N, et al. . A measles outbreak in an underimmunized Amish
community in Ohio. N Engl J Med. 2016;375(14):1343-1354. doi:10.1056/NEJMoa1602295 [PubMed:
27705270] [CrossRef: 10.1056/NEJMoa1602295]
28. Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K; Centers for Disease Control and
Prevention (CDC) . Measles outbreak—California, December 2014-February 2015. MMWR Morb Mortal
Wkly Rep. 2015;64(6):153-154. [PMCID: PMC4584705] [PubMed: 25695321]
29. Hall V, Banerjee E, Kenyon C, et al. . Measles outbreak—Minnesota April-May 2017. MMWR Morb
Mortal Wkly Rep. 2017;66(27):713-717. doi:10.15585/mmwr.mm6627a1 [PMCID: PMC5687591]
[PubMed: 28704350] [CrossRef: 10.15585/mmwr.mm6627a1]
30. Hagmann S, LaRocque RC, Rao SR, et al. ; Global TravEpiNet Consortium . Pre-travel health
preparation of pediatric international travelers: analysis from the Global TravEpiNet consortium. J
Pediatric Infect Dis Soc. 2013;2(4):327-334. doi:10.1093/jpids/pit023 [PubMed: 26619495] [CrossRef:
10.1093/jpids/pit023]
31. Angelo KM, Gastañaduy PA, Walker AT, et al. . Spread of measles in Europe and implications for US
travelers. Pediatrics. 2019;144(1):e20190414. doi:10.1542/peds.2019-0414 [PMCID: PMC6657509]
[PubMed: 31209161] [CrossRef: 10.1542/peds.2019-0414]

Figures and Tables

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable

12/20

5/18/2021

Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers

Table 1.
Differences Between the Routine MMR Vaccination Schedule and the MMR Vaccination
Recommendations for US Pediatric International Travelers
MMR Vaccination
6
Routine
International
15
travelers

Infants (6 to <12

Preschool Aged (1 to <6

mo)

y)

None
b
1 Dose

School Aged (6 to <18 y)

a
1 Dose: 12-15 mo of age 2 Doses: 12-15 mo of age and 4-6 y of
a
age
c
c
2 Doses
2 Doses

Abbreviation: MMR, measles-mumps-rubella.
a

For children aged 1 year to 4 and 6 years who have not received 1 dose of MMR vaccine after age 12 months, the
catch-up immunization schedule recommends 1 dose of MMR vaccine. For children aged between 4 and 6 years to
younger than 18 years who have not received MMR vaccine after age 12 months, the catch-up immunization schedule
recommends 2 doses of MMR vaccine administered at least 28 days apart.
b
A total of 3 lifetime doses of MMR vaccine is recommended for children who received a dose of MMR vaccine
before 12 months of age.
c
The second dose of MMR vaccine should be given at least 28 days after the first dose.
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Table 2.
Traveler and Site Characteristics of Global TravEpiNet Pretravel Consultations for Pediatric
Travelers Eligible for MMR Vaccination (2009-2018)
Characteristic Total
(N =

Vaccinated Not
(n = 1182)

2864)

P
Not Vaccinated
a
Vaccinated Value Total Clinician Guardian Referred P
a
(n = 1682)
(n =
Decision Refusal
to
Value
1682) (n = 621)

(n = 612)

Another
Clinician
(n =
b
449)

Sex, No. (%)
Female

1389

576 (48.7)

813 (48.3)

(48.5)
Male

1475

606 (51.3)

869 (51.7)

813
.08

(51.5)

295

296 (48.4) 222

(48.3) (47.5)
869

326

(49.4)
316 (51.6) 227

(51.7) (52.5)

.91

(50.6)

Age group,
No. (%)
Infants, 6 to

365

<12 mo

(12.7)

Preschool-

2161

204 (17.2)

161 (9.6)

to <18 y

70 (11.3)

27 (4.4)

64 (14.2)

497

398 (65.0) 327

(9.6)
939 (79.4)

1222 (72.6)

aged, 1 to <6 y (75.5)
School-aged, 6 338

161

39 (3.3)

.045

299 (17.8)

1222

(72.6) (80.0)
299

(11.8)

(72.8)

54 (8.7)

187 (30.6) 58 (12.9)

120

285 (46.6) 152

<.001

(17.8)

Previous
MMR
vaccinations,
No. (%)
0

891

334 (28.3)

557 (33.1)

(31.1)
1

1973

848 (71.7)

1125 (66.9)

557
.12

68.9)

(33.1) (19.3)
1125

501

(66.9) (80.7)

(33.8)
327 (53.4) 297

<.001

(66.1)

Region of
travel, No.
c
(%)
Africa

1634

739 (62.5)

895 (53.2)

(57 1)

.007

895

324

(53 2) (52 2)

392 (64.1) 179

.01

(39 9)

Open in a separate window
Abbreviation: MMR, measles-mumps-rubella.
a

Categorical variables: 2-sided P values were obtained from the Cochran-Mantel-Haenszel test and indicate whether
the association of the characteristic and the outcome is statistically significant after adjusting for clinic site. Twosided P values for testing the association of type of site or US census region were obtained from χ2 test of
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independence. Continuous variables: P values were obtained from the Wilcoxon/Kruskal-Wallis test and indicate
whether the distribution of the variable is significantly different in the outcome groups.
b
The 16 pediatric travelers not vaccinated because of vaccine unavailability were included with those referred to
another clinician for demographic analysis.
c
Column percentages may not sum to 100% because more than 1 selection was allowed.
d
Midwest excluded from this comparison given its low sample size.
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Figure 1.

Reasons for Nonvaccination Among Pediatric Travelers Eligible for Measles-Mumps-Rubella (MMR)
Vaccination at 29 Global TravEpiNet Clinic Sites (2009-2018)
All travelers included all MMR vaccination–eligible pediatric travelers (infants, aged 6 to <12 months; preschoolaged, aged 1 to <6 years; and school-aged, aged 6 to <18 years).
a

Clinicians did not collect reason for guardian refusal of MMR vaccination (January 1, 2009, to June 30, 2012).

b

Clinicians were prompted to ask guardians to specify 1 of 3 reasons for refusal of MMR vaccination (July 1,
2012, to December 31, 2018).
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Table 3.
Association of Traveler and Site Characteristics With MMR Vaccination at Global
TravEpiNet Sites Among Pediatric Travelers Eligible for MMR Vaccination (2009-2018)a
Variable

Model 1
OR (95% CI)

Model 2
P Value OR (95% CI)

P Value

Sex
Male

1 [Reference]

Female

1.04 (0.83-1.29)

.74

1 [Reference]
1.14 (0.95-1.37)

.13

Age group
Infants, 6 to <12 mo

1 [Reference]

1 [Reference]

Preschool-aged, 1 to <6 y

0.77 (0.53-1.11) <.001

0.83 (0.58-1.20) <.001

School-aged, 6 to <18 y

0.32 (0.24-0.42)

0.26 (0.14-0.47)

Africa

1.86 (1.15-3.01) .008

1.74 (1.17-2.58) .004

Americas

1.07 (0.63-1.80) .80

1.17 (0.66-2.07) .56

Eastern Mediterranean

0.77 (0.45-1.33) .33

0.70 (0.41-1.21) .18

Europe

0.91 (0.61-1.36) .62

1.05 (0.78-1.40) .75

Southeast Asia

0.97 (0.48-1.95) .93

1.26 (0.68-2.32) .44

Western Pacific

0.76 (0.44-1.30) .29

0.90 (0.56-1.45) .66

<14 d

1 [Reference]

1 [Reference]

≥14 d

1.17 (0.82-1.67)

Region of travel

Duration of travel
.36

1.19 (0.88-1.62)

.24

Purpose of travel
Visiting friends or relatives 1 [Reference]
Leisure

0.49 (0.26-0.94)

Service or education

0.18 (0.07-0.48)

Other

0.60 (0.36-1.00)

1 [Reference]
.002

0.64 (0.38-1.08)
0.47 (0.16-1.34)

.22

0.77 (0.49-1.19)

Time until departure
<14 d

1 [Reference]

≥14 d

1.13 (0.87-1.48)

Type of site

.34

1 [Reference]
1.18 (0.88-1.59)

.24

<.001

Academic center

1 [Reference]

Nonacademic center

0.04 (0.01-0.20)

<.001

NA
NA

NA

Open in a separate window
Abbreviations: MMR, measles-mumps-rubella; NA, not applicable; OR, odds ratio.
a

Models used Taylor linearization methods, a form of generalized estimating evaluations, to adjust for the clustering
of patients within sites.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC6902185/?report=printable

19/20

5/18/2021

Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers

Figure 2.

Measles-Mumps-Rubella (MMR) Vaccination and Reasons for Nonvaccination Among MMR Vaccination–
Eligible Pediatric Travelers at Academic Sites and Nonacademic Sites, Stratified by US Census Region of
Global TravEpiNet Site
Travelers not vaccinated because of unavailability of MMR vaccine were included with those who were referred
to another clinician. No pediatric travelers evaluated at academic centers in the Midwest were eligible for MMR
vaccination.
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